NYSE:XON - Intrexon Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $14.83 +0.33 (+2.28 %) (As of 08/22/2018 03:00 AM ET)Previous Close$14.50Today's Range$14.54 - $15.0552-Week Range$10.26 - $20.67Volume790,500 shsAverage Volume1.54 million shsMarket Capitalization$1.86 billionP/E Ratio-16.12Dividend YieldN/ABeta1.08 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland. Receive XON News and Ratings via Email Sign-up to receive the latest news and ratings for XON and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Commercial physical research Sub-IndustryN/A SectorMedical SymbolNYSE:XON CUSIPN/A Webwww.dna.com Phone301-556-9900 Debt Debt-to-Equity Ratio0.01 Current Ratio1.78 Quick Ratio1.53 Price-To-Earnings Trailing P/E Ratio-16.12 Forward P/E Ratio-17.24 P/E GrowthN/A Sales & Book Value Annual Sales$230.98 million Price / Sales8.30 Cash FlowN/A Price / CashN/A Book Value$4.29 per share Price / Book3.46 Profitability EPS (Most Recent Fiscal Year)($0.92) Net Income$-117,010,000.00 Net Margins-82.17% Return on Equity-16.67% Return on Assets-11.07% Miscellaneous Employees1,006 Outstanding Shares129,290,000Market Cap$1.86 billion Intrexon (NYSE:XON) Frequently Asked Questions What is Intrexon's stock symbol? Intrexon trades on the New York Stock Exchange (NYSE) under the ticker symbol "XON." How were Intrexon's earnings last quarter? Intrexon Corp (NYSE:XON) released its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.28. The biotechnology company had revenue of $45.30 million for the quarter, compared to analysts' expectations of $51.70 million. Intrexon had a negative return on equity of 16.67% and a negative net margin of 82.17%. During the same period last year, the firm posted ($0.16) earnings per share. View Intrexon's Earnings History. When is Intrexon's next earnings date? Intrexon is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Intrexon. What price target have analysts set for XON? 6 brokerages have issued 12-month price objectives for Intrexon's shares. Their predictions range from $12.00 to $72.00. On average, they expect Intrexon's stock price to reach $36.00 in the next year. This suggests a possible upside of 142.8% from the stock's current price. View Analyst Price Targets for Intrexon. What is the consensus analysts' recommendation for Intrexon? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intrexon in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intrexon. Are investors shorting Intrexon? Intrexon saw a increase in short interest in the month of July. As of July 13th, there was short interest totalling 31,490,415 shares, an increase of 30.0% from the June 29th total of 24,224,874 shares. Based on an average daily trading volume, of 1,116,788 shares, the short-interest ratio is presently 28.2 days. Currently, 51.8% of the shares of the stock are sold short. View Intrexon's Current Options Chain. Who are some of Intrexon's key competitors? Some companies that are related to Intrexon include PRA Health Sciences (PRAH), EXACT Sciences (EXAS), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), VIRALYTICS Ltd/S (VRACY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL) and HedgePath Pharmaceuticals (HPPI). Who are Intrexon's key executives? Intrexon's management team includes the folowing people: Mr. Randal J. Kirk, Chairman & CEO (Age 65)Mr. Rick L. Sterling, Chief Financial Officer (Age 54)Mr. Donald P. Lehr, Chief Legal Officer & Corp. Sec. (Age 43)Mr. Robert F. Walsh III, Sr. VP of Energy & Fine Chemicals Platforms (Age 60)Mr. Jeffrey Thomas Perez, Sr. VP of Intellectual Property Affairs (Age 46) Has Intrexon been receiving favorable news coverage? Headlines about XON stock have trended somewhat positive on Wednesday, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intrexon earned a media and rumor sentiment score of 0.10 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Intrexon. Who are Intrexon's major shareholders? Intrexon's stock is owned by a number of of retail and institutional investors. Top institutional investors include Third Security LLC (45.87%), Iridian Asset Management LLC CT (4.17%), FMR LLC (3.85%), BlackRock Inc. (3.59%), First Trust Advisors LP (2.48%) and Morgan Stanley (2.41%). Company insiders that own Intrexon stock include Andrew J Last, Dean J Mitchell, Donald P Lehr, Fred Hassan, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk and Robert B Shapiro. View Institutional Ownership Trends for Intrexon. Which institutional investors are selling Intrexon stock? XON stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Frontier Capital Management Co. LLC, First Trust Advisors LP, Elephas Investment Management Ltd, FMR LLC, State Board of Administration of Florida Retirement System, Sei Investments Co. and Commonwealth Equity Services LLC. View Insider Buying and Selling for Intrexon. Which institutional investors are buying Intrexon stock? XON stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Third Security LLC, Bank of America Corp DE, Schwab Charles Investment Management Inc., Canada Pension Plan Investment Board, Peregrine Capital Management LLC and State of Wisconsin Investment Board. Company insiders that have bought Intrexon stock in the last two years include Andrew J Last, Dean J Mitchell, Donald P Lehr, Fred Hassan, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk and Robert B Shapiro. View Insider Buying and Selling for Intrexon. How do I buy shares of Intrexon? Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Intrexon's stock price today? One share of XON stock can currently be purchased for approximately $14.83. How big of a company is Intrexon? Intrexon has a market capitalization of $1.86 billion and generates $230.98 million in revenue each year. The biotechnology company earns $-117,010,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Intrexon employs 1,006 workers across the globe. How can I contact Intrexon? Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected] MarketBeat Community Rating for Intrexon (NYSE XON)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 286 (Vote Outperform)Underperform Votes: 265 (Vote Underperform)Total Votes: 551MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe XON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XON will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/22/2018 by MarketBeat.com StaffFeatured Article: What does relative strength index mean?